<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02426073</url>
  </required_header>
  <id_info>
    <org_study_id>5312/15</org_study_id>
    <nct_id>NCT02426073</nct_id>
  </id_info>
  <brief_title>Glucose Metabolism, Muscle Mass/Function and Inflammation in the Elderly</brief_title>
  <official_title>Pilot Observational Study to Characterize Glucose Metabolism, Muscle Mass/Function and Inflammatory Profile in Elderly Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Roma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <brief_summary>
    <textblock>
      A thorough characterization of glucose metabolism and &quot;inflammaging&quot; in elderly subjects will&#xD;
      help determine to what extent each of these factors affects muscle mass/function and&#xD;
      contributes to age-related muscle wasting. The investigators will correlate patterns of&#xD;
      insulin secretion/sensitivity with &quot;muscle &quot;quality/quantity&quot; in diabetic and non-diabetic&#xD;
      elderlies (≥70 years old). By comparing different groups (healthy, sarcopenic, diabetic,&#xD;
      diabetic/sarcopenic), the investigators expect to identify an &quot;oxidative/inflammatory&#xD;
      signature&quot; (e.g., circulating interleukins/myokines, plasma antioxidant capacity) specific&#xD;
      for the sarcopenic phenotype and related to muscle insulin resistance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory markers (TNF-α, interleukin-1, interleukin-2, interleukin-6, RANKL, Myostatin and GDF11)</measure>
    <time_frame>2 years</time_frame>
    <description>The primary objective of the study is to detect differences in inflammatory markers in the four groups</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Sarcopenia</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>HE</arm_group_label>
    <description>Healthy elderlies</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DM</arm_group_label>
    <description>Elderlies with type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SA</arm_group_label>
    <description>Elderlies with sarcopenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DS</arm_group_label>
    <description>Elderlies with both type 2 diabetes and sarcopenia</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Elderly (≥ 70 years) subjects&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 2 diabetes mellitus: patients taking drugs for diabetes will be diagnosed as&#xD;
             having diabetes. In all other patients, a diagnosis will be established according to&#xD;
             the criteria of the American Diabetes Association&#xD;
&#xD;
          -  Sarcopenia (non-severe): individuals with low muscle mass and either low muscle&#xD;
             strength or low physical performance will be diagnosed with sarcopenia, according to&#xD;
             the criteria of the European Working Group on Sarcopenia in Older People (EWGSOP)&#xD;
&#xD;
          -  Healthy volunteers: no diabetes, no sarcopenia and none of the exclusion criteria&#xD;
&#xD;
        Exclusion Criteria (overall population):&#xD;
&#xD;
          -  acute diseases,&#xD;
&#xD;
          -  chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  conditions associated with sarcopenia/altered body composition (e.g. disability,&#xD;
             altered endocrine function, chronic diseases, nutritional deficiencies, cancer),&#xD;
&#xD;
          -  obesity (body mass index ≥30 kg/m2)&#xD;
&#xD;
          -  moderate-severe hepatic disease,&#xD;
&#xD;
          -  chronic kidney disease (estimated glomerular filtration rate &lt;30 ml/min per 1.73m2),&#xD;
&#xD;
          -  metal prostheses,&#xD;
&#xD;
          -  recent or ongoing infection,&#xD;
&#xD;
          -  inability or unwillingness to provide informed consent&#xD;
&#xD;
        Exclusion Criteria (diabetic population):&#xD;
&#xD;
          -  type 1 diabetes,&#xD;
&#xD;
          -  hemoglobin A1c &gt;8.5% (69 mmol/mol),&#xD;
&#xD;
          -  basal-bolus insulin therapy,&#xD;
&#xD;
          -  insulin pump therapy,&#xD;
&#xD;
          -  proliferative diabetic retinopathy,&#xD;
&#xD;
          -  diabetic foot.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Giaccari, MD, PhD</last_name>
      <phone>00390630156664</phone>
      <email>giaccari@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Giaccari, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giovambattista Pani, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Calibita - Fatebenefratelli Isola Tiberina</name>
      <address>
        <city>Rome</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simona Frontoni, MD</last_name>
      <email>frontoni@uniroma2.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>April 21, 2015</study_first_submitted>
  <study_first_submitted_qc>April 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2015</study_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Alfredo Pontecorvi</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Inflammaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

